| Literature DB >> 35207330 |
Young Seon Kim1, Won Seob Lee2, Bo-Yoon Park2, Manki Choi2, Jun Ho Lee2, Young Kyung Bae3, Il-Kug Kim2.
Abstract
BACKGROUND: Acellular dermal matrix (ADM) in implant-based breast reconstruction can show various ultrasound (US) findings. However, there are limited reports on the US features of the ADM. The aims of this study were to evaluate US findings of the ADM in implant-based breast reconstruction and correlate them with histopathological findings.Entities:
Keywords: acellular dermal matrix; breast implants; mammaplasty; ultrasonography
Year: 2022 PMID: 35207330 PMCID: PMC8877379 DOI: 10.3390/jcm11041057
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Categorizing ultrasound (US) finding of the acellular dermal matrix (ADM, yellow dotted line) in implant-based breast reconstruction (176 patients, 207 US findings). Normal ADM (control) shows consistent thickness with homogeneous echogenicity. Abnormal findings were classified as: type 1: ADM shows focal thickening with decreased echogenicity (arrow); type 2: diffusely increased echogenicity; and type 3: bright echogenic spots (arrowheads) within the ADM.
Figure 2Correlations between the acellular dermal matrix (ADM) ultrasound and histopathologic findings. Histologically, type 1 shows patchy areas with chronic inflammatory infiltrate with a few foreign-body giant cells and neovascularization. Type 2 shows dense collagen bundles without degenerative or inflammatory changes and a few cells. Type 3 shows multiple empty spaces inside the ADM.
Multiple logistic regression model of abnormal ultrasonographic findings in ADM risk factor.
| Control (%) | Type 1 (%) | Type 2 (%) | Type 3 (%) | OR | 95% CI | ||
|---|---|---|---|---|---|---|---|
| No. | 108 | 28 | 23 | 48 | |||
| Age at breast reconstruction, years | |||||||
| Mean ± SD | 45.5 ± 7.36 | 48.5 ± 9.14 | 51.6 ± 8.01 | 48.9 ± 7.74 | 1.074 | 1.022–1.129 | 0.005 * |
| BMI | |||||||
| Mean ± SD | 21.9 ± 2.87 | 23.1 ± 2.68 | 23.2 ± 3.06 | 23.5 ± 2.96 | 1.062 | 0.901–1.252 | 0.475 |
| Chemotherapy | 40 (37.0) | 14 (50.0) | 8 (34.8) | 23 (47.9) | 2.792 | 1.272–6.127 | 0.010 * |
| Radiotherapy | 13 (12.0) | 2 (7.1) | 2 (8.7) | 8 (16.7) | 0.692 | 0.236–2.026 | 0.501 |
| Implant volume, cc | |||||||
| Mean ± SD | 224.6 ± 83.58 | 255.9 ± 108.84 | 250.7 ± 113.25 | 260.4 ± 103.49 | 1.002 | 0.997–1.007 | 0.423 |
| Implant surface | |||||||
| Macrotextured | 91 (84.3) | 15 (53.6) | 18 (78.3) | 30 (62.5) | Reference | ||
| Microtextured | 3 (2.8) | 7 (25.0) | 3 (13.0) | 10 (20.8) | 5.403 | 1.284–22.736 | 0.021 * |
| Smooth | 14 (13.0) | 6 (21.4) | 2 (8.7) | 8 (16.7) | 2.302 | 0.844–6.277 | 0.103 |
| ADM type | |||||||
| Megaderm | 69 (63.9) | 7 (25.0) | 7 (30.4) | 6 (12.5) | Reference | ||
| CGCryoderm | 29 (26.9) | 20 (71.4) | 15 (65.2) | 38 (79.2) | 8.167 | 3.722–17.922 | <0.005 * |
| Alloderm | 10 (9.3) | 1 (3.6) | 1 (4.3) | 2 (4.2) | 1.659 | 0.421–6.546 | 0.470 |
| DermaCELL | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (4.2) | N/A | 0–0 | 1.000 |
| Complication | |||||||
| Capsular contracture | 19 (17.6) | 4 (14.3) | 5 (21.7) | 7 (14.6) | 0.799 | 0.31–2.062 | 0.643 |
| Infection | 2 (1.9) | 0 (0.0) | 1 (4.3) | 1 (2.1) | 5.410 | 0.528–55.421 | 0.155 |
| Necrosis | 2 (1.9) | 0 (0.0) | 1 (4.3) | 1 (2.1) | 0.285 | 0.021–3.947 | 0.349 |
| Wound dehiscence | 6 (5.6) | 1 (3.6) | 0 (0.0) | 2 (4.2) | 0.542 | 0.069–4.233 | 0.559 |
| Seroma | 0 (0.0) | 1 (3.6) | 2 (8.7) | 2 (4.2) | N/A | 0–0 | 1.000 |
BMI, body mass index; ADM, acellular dermal matrix; SD, standard deviation; OR, odds ratio; CI, confidence interval; * p < 0.05.
Figure 3Acellular dermal matrix (ADM) ultrasound (US) findings in implant-based breast reconstruction. US imaging immediately after surgery (postoperative day 4) shows bright, hyperechoic dots diffusely visible in the ADM (arrowheads, left). After six months, the number of bright echogenic spots in the ADM reduced considerably (arrowhead, right).
Figure 4Cancer recurrence identified by ultrasound (US) examination after implant-based breast reconstruction. The image shows an irregular-shaped, hypoechoic mass (yellow arrow) located on the superficial aspect of the fibrous capsule (yellow dotted line). In this patient, the acellular dermal matrix layer was not visible on the US image. Histopathological examination indicated that the cancer mass was attached very close to the fibrous capsule.